Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's Income from Continuing Operations rose 79.78% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.5 million, marking a year-over-year decrease of 239.91%. This contributed to the annual value of -$14.4 million for FY2025, which is 14.99% down from last year.
  • As of Q3 2025, Aytu Biopharma's Income from Continuing Operations stood at $2.0 million, which was up 109.78% from -$20.1 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Income from Continuing Operations registered a high of $3.9 million during Q1 2025, and its lowest value of -$53.3 million during Q1 2022.
  • Its 3-year average for Income from Continuing Operations is -$3.2 million, with a median of -$2.3 million in 2024.
  • Per our database at Business Quant, Aytu Biopharma's Income from Continuing Operations plummeted by 966.05% in 2023 and then soared by 272.20% in 2025.
  • Over the past 5 years, Aytu Biopharma's Income from Continuing Operations (Quarterly) stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then soared by 108.95% to $599,000 in 2023, then rose by 13.86% to $682,000 in 2024, then surged by 79.78% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, -$20.1 million for Q2 2025, and $3.9 million during Q1 2025.